EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Tocilizumab Biosimilars versus Reference Tocilizumab in Rheumatoid Arthritis: A Meta-Analysis of Pharmacokinetic Biosimilarity, Efficacy, Safety, and Immunogenicity

Young Ho Lee, Gwan Gyu Song

Pharmacology · 08.05.2026 · 1-14

DOI: 10.1159/000552447 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Pharmacology, online erschienen am 08.05.2026. Verfasst von Young Ho Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Korea University College of Medicine, Seoul, Republic of Korea, lyhcgh@korea.ac.kr. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antibodies, Monoclonal, Humanized, Biosimilar Pharmaceuticals, Antirheumatic Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of the study was to systematically evaluate the efficacy, safety, immunogenicity, and pharmacokinetics (PK) of tocilizumab biosimilars compared to reference tocilizumab (r-TCZ) in patients with rheumatoid arthritis (RA) and healthy volunteers.

Methods

We searched PubMed, Embase, and Cochrane CENTRAL for phase I and III randomized controlled trials (RCTs) comparing tocilizumab biosimilars vs. r-TCZ. Primary outcomes included change from baseline in DAS28-ESR, ACR20/50/70 response rates, adverse events (AEs), serious AEs (SAEs), anti-drug antibody (ADA) positivity, and PK parameters (AUC0−inf, Cmax, and AUC0−last). Random-effects meta-analyses were performed using mean difference (MD), risk ratio (RR), and geometric mean ratio (GMR) with 95% or 90% confidence intervals (CIs). This systematic review and meta-analysis have been registered in PROSPERO (CRD420251270353).

Results

Eight studies met the inclusion criteria, comprising 3 phase III RCTs (n = 1,696 RA patients) and 5 phase I RCTs (n = 1,363 healthy volunteers), for a total of 3,059 participants. In RA patients, biosimilars demonstrated equivalent efficacy to r-TCZ at week 24, with no significant differences in DAS28-ESR change (MD −0.06; 95% CI: −0.19 to 0.06; I2 = 0%) or ACR20 response rates (RR 1.03; 95% CI: 0.96–1.10; I2 = 0). Results for ACR50 and ACR70 were similarly balanced. Safety profiles were comparable (any AE: RR 1.01; 95% CI: 0.94–1.08), as was immunogenicity (ADA positivity: RR 1.28; 95% CI: 0.99–1.65). In healthy volunteers, PK biosimilarity was confirmed across intravenous and subcutaneous routes with pooled GMRs (90% CI) of 104.5% (101.2–107.9%) for AUC0−inf, 101.4% (98.5–104.4%) for Cmax, and 102.3% (97.8–106.9%) for AUC0−last; all pooled CIs lay entirely within the 80–125% regulatory acceptance range (I2 ≤ 35).

Conclusion

Tocilizumab biosimilars exhibit therapeutic similarity in RA patients and pharmacokinetic biosimilarity in healthy volunteers compared to r-TCZ, with comparable safety and immunogenicity, supporting their use as credible, cost-effective alternatives in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAntibodies, Monoclonal, HumanizedBiosimilar PharmaceuticalsAntirheumatic AgentsHumansRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

BiosimilarMeta-analysisPharmacokineticsRheumatoid arthritisTherapeutic similarityTocilizumab

Substanzen

Antibodies, Monoclonal, HumanizedBiosimilar PharmaceuticalstocilizumabAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Rheumatology, Korea University College of Medicine, Seoul, Republic of Korea, lyhcgh@korea.ac.kr.
  • Department of Rheumatology, Korea University College of Medicine, Seoul, Republic of Korea.

Zitieren

APA

Lee, Y. H., & Song, G. G. (2026). Tocilizumab Biosimilars versus Reference Tocilizumab in Rheumatoid Arthritis: A Meta-Analysis of Pharmacokinetic Biosimilarity, Efficacy, Safety, and Immunogenicity. Pharmacology, 1-14. https://doi.org/10.1159/000552447

Vancouver

Lee YH, Song GG. Tocilizumab Biosimilars versus Reference Tocilizumab in Rheumatoid Arthritis: A Meta-Analysis of Pharmacokinetic Biosimilarity, Efficacy, Safety, and Immunogenicity. Pharmacology. 2026:1-14. doi:10.1159/000552447

BibTeX
@article{Lee2026,
  author = {Lee, Young Ho and Song, Gwan Gyu},
  title = {Tocilizumab Biosimilars versus Reference Tocilizumab in Rheumatoid Arthritis: A Meta-Analysis of Pharmacokinetic Biosimilarity, Efficacy, Safety, and Immunogenicity},
  journal = {Pharmacology},
  year = {2026},
  pages = {1--14},
  doi = {10.1159/000552447}
}
Kostenlos starten →